The future of medicine lies in ever greater precision, not only when it comes to diagnosis but also drug dosage. The blood work that medical staff rely on is generally a snapshot indicative of the moment the blood is drawn before it undergoes hours, or even days, of analysis. Now, several EPFL laboratories are working on devices allowing constant analysis over as long a period as possible. The latest development is the biosensor chip which was unveiled at the International Symposium on Circuits and Systems (ISCAS).
The team state that this is the world’s first chip capable of measuring not just pH and temperature, but also metabolism-related molecules like glucose, lactate and cholesterol, as well as drugs. A group of electrochemical sensors works with or without enzymes, which means the device can react to a wide range of compounds, and it can do so for several days or even weeks.
The researchers explain that this one-centimetre square device contains three main components, a circuit with six sensors, a control unit that analyses incoming signals, and a radio transmission module. It also has an induction coil that draws power from an external battery attached to the skin by a patch. A simple plaster holds together the battery, the coil and a Bluetooth module used to send the results immediately to a mobile phone.
The chip was successfully tested in vivo on mice at the Institute for Research in Biomedicine (IRB), where researchers were able to constantly monitor glucose and paracetamol levels without a wire tracker getting in the way of the animals’ daily activities. The team state that the results were extremely promising, which means that clinical tests on humans could take place in three to five years, especially since the procedure is only minimally invasive, with the chip being implanted just under the epidermis.
The lab surmise that knowing the precise and real-time effect of drugs on the metabolism is one of the keys to the type of precision medicine that the medical community are striving for.
Michelle Petersen is the founder of Healthinnovations, having worked in the health and science industry for over 21 years, which includes tenure within the NHS and Oxford University. Healthinnovations is a publication that has reported on, influenced, and researched current and future innovations in health for the past decade.
Michelle has been picked up as an expert writer for Informa publisher’s Clinical Trials community, as well as being listed as a blog source by the world’s leading medical journals, including the acclaimed Nature-Springer journal series.
Healthinnovations is currently indexed by the trusted Altmetric and PlumX metrics systems, respectively, as a blog source for published research globally. Healthinnovations is also featured in the world-renowned BioPortfolio, BioPortfolio.com, the life science, pharmaceutical and healthcare portal.
Most recently the Texas A&M University covered The Top 10 Healthinnovations series on their site with distinguished Professor Stephen Maren calling the inclusion of himself and his team on the list a reflection of “the hard work and dedication of my students and trainees”.
Michelle Petersen’s copy was used in the highly successful marketing campaign for the mega-hit film ‘Jumanji: The Next Level, starring Jack Black, Karen Gilian, Kevin Hart and Dwayne ‘The Rock’ Johnson. Michelle Petersen’s copywriting was part of the film’s coverage by the Republic TV network. Republic TV is the most-watched English language TV channel in India since its inception in 2017.
An avid campaigner in the fight against child sex abuse and trafficking, Michelle is a passionate humanist striving for a better quality of life for all humans by helping to provide traction for new technologies and techniques within healthcare.